4.8 Review

IL-6 pathway in the liver: From physiopathology to therapy

Journal

JOURNAL OF HEPATOLOGY
Volume 64, Issue 6, Pages 1403-1415

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2016.02.004

Keywords

Interleukin-6; Interleukin-6-receptor; Trans-signaling; Inflammation; Cancer; Liver regeneration

Funding

  1. Deutsche Forschungsgemeinschaft Bonn, Germany [SFB 841, SFB 877]
  2. Deutsche Forschungsgemeinschaft Bonn, Germany (Cluster of Excellence 'Inflammation at Interfaces')

Ask authors/readers for more resources

Interleukin 6 (IL-6) is a pleiotropic four-helix-bundle cytokine that exerts multiple functions in the body. In the liver, IL-6 is an important inducer of the acute phase response and infection defense. IL-6 is furthermore crucial for hepatocyte homeostasis and is a potent hepatocyte mitogen. It is not only implicated in liver regeneration, but also in metabolic function of the liver. However, persistent activation of the IL-6 signaling pathway is detrimental to the liver and might ultimately result in the development of liver tumors. On target cells IL-6 can bind to the signal transducing subunit gp130 either in complex with the membrane-bound or with the soluble IL-6 receptor to induce intracellular signaling. In this review we describe how these different pathways are involved in the physiology and pathophyiology of the liver. We furthermore discuss how IL-6 pathways can be selectively inhibited and therapeutically exploited for the treatment of liver pathologies. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available